{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T15:04:37Z","timestamp":1745593477882},"reference-count":6,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>We report a case of a 66-year-old woman with small cell lung cancer (stage IIB, T2N1M0), who received immunotherapy with nivolumab monthly for 2 months and then presented with thyrotoxic symptoms associated with suppressed thyroid-stimulating hormone levels and elevated free thyroid hormone levels, although previous thyrotropin performed 1 month ago was normal. Thyroid uptake and scan demonstrated diffusely decreased uptake in both thyroid lobes. The 4-hour percentage uptake was 0.7%, and the 24-hour percentage uptake was 0.3%. This was followed by development of hypothyroidism within few weeks. Findings suggested drug-induced thyroiditis secondary to nivolumab therapy.<\/jats:p>","DOI":"10.1097\/rlu.0000000000003074","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T21:21:58Z","timestamp":1601500918000},"page":"719-721","source":"Crossref","is-referenced-by-count":2,"title":["Immunotherapy and Thyroid Dysfunction"],"prefix":"10.1097","volume":"45","author":[{"given":"Maria Laura","family":"Gregorio","sequence":"first","affiliation":[{"name":"Department of Radiology, Louisiana State University Health Sciences Center\u2013Shreveport"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Sebastian","family":"Gomez","sequence":"additional","affiliation":[{"name":"Department of Radiology, Louisiana State University Health Sciences Center\u2013Shreveport"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surender","family":"Arora","sequence":"additional","affiliation":[{"name":"Overton Brooks Veterans Affairs Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Ramachandran","sequence":"additional","affiliation":[{"name":"Overton Brooks Veterans Affairs Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amol","family":"Takalkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,7,10]]},"reference":[{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.radcr.2017.09.008","article-title":"Acute inflammatory thyromegaly following checkpoint inhibition: a new imaging entity?","volume":"13","year":"2018","journal-title":"Radiol Case Rep"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2967\/jnmt.117.204933","article-title":"18F-FDG PET\/CT can predict development of thyroiditis due to immunotherapy for lung cancer","volume":"46","year":"2018","journal-title":"J Nucl Med Technol"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1089\/thy.2016.0562","article-title":"Clinical features of nivolumab-induced thyroiditis: a case series study","volume":"27","year":"2017","journal-title":"Thyroid"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3389\/fendo.2018.00813","article-title":"Nivolumab induced thyroid dysfunction: unusual clinical presentation and challenging diagnosis","volume":"9","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"bib7-20230925","first-page":"1225","article-title":"Potential risk factors for nivolumab-induced thyroid dysfunction","volume":"31","year":"2017","journal-title":"In Vivo"},{"key":"bib8-20230925","first-page":"1","article-title":"Nivolumab-induced thyroid dysfunction in patients with lung cancer","volume":"66","year":"2018","journal-title":"Endocrinol Diabetes Nutr"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003074","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T06:09:08Z","timestamp":1695622148000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003074"}},"subtitle":["Relevance to Nuclear Medicine"],"short-title":[],"issued":{"date-parts":[[2020,7,10]]},"references-count":6,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003074","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,10]]}}}